Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions

• Status: Completed
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The rationale of the study is to clarify whether the supplementation of irbesartan with ciprofibrate could increase the antihypertensive effect, could improve the endothelial functions, and/or could affect the atherogenic small-dense LDL-, oxydized LDL concentrations, onto the paraoxinase activity and on the CRP and insulin levels.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Collaborator: Bristol-Myers Squibb
• Treatments: Ciprofibrate; Irbesartan

Criteria

Inclusion Criteria:

• hypertensive + dyslipidemic + damaged endothelial function

Exclusion Criteria:

• hepatic and kidney damage,

• IDDM (Insulin Dependent Diabetes Mellitus)

• Freckson V type hyperlipoproteinaemia

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.